Skip to content
  • facebook.com
  • twitter.com
  • t.me
  • instagram.com
  • youtube.com
BioTechGrid BioTechGrid
  • Home
  • Biotechnology
  • Medical Technology
  • Research
  • Genetics
  • Press Releases
    • Business Wire
    • GlobeNewswire
    • PRNewswire
  • Contact
  • Home
  • Biotechnology
  • BioMarin axes $270M rare disease asset after missing phase 3 endpoint

BioMarin axes $270M rare disease asset after missing phase 3 endpoint

August 7, 2026Posted inBiotechnology

BioMarin Pharmaceutical has ended development of BMN 401 in all indications months after reporting mixed phase 3 data on the rare disease prospect.

Post navigation

Previous Post
Novo Nordisk’s CFO on the oral Wegovy rollout and beyond
Next Post
CAFs Suppress Pancreatic Cancer Immunity Through the Lin28B-STING Axis cafs-suppress-pancreatic-cancer-immunity-through-the-lin28b-sting-axis

Recent Posts

  • FWB-SMOTE Algorithm Outperforms Eleven Benchmarks on Imbalanced Datasets Across Three Classifiers
  • Explainable Deep Learning Model Accurately Detects Industrial Network Cyber Threats
  • Smoothing Methods Enhance Machine Learning State-of-Health Predictions for Lithium-Ion Batteries
  • Forest Conditions Outside National Parks Strongly Influence Bird Presence Within Them
  • Maternal Poor Sleep Quality Linked to Congenital Heart Defects in Offspring

Archives

  • November 2026
  • October 2026
  • September 2026
  • August 2026
  • July 2026
  • September 2024
  • August 2024
  • March 2024
  • September 2023

Privacy Policy    Terms

Scroll to Top